Wellington Management Group
CTMX icon

Wellington Management Group’s CytomX Therapeutics CTMX Stock Holding History

Wellington Management Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4M Buy
5,168,961
+1,585,976
+44% +$6.06M ﹤0.01% 1077
2026
Q1 		$16.8M Buy
+3,582,985
New +$18.2M ﹤0.01% 1079
2020
Q1 		– Sell
-130,332
Closed -$1.08M – 1937
2019
Q4 		$1.08M Sell
130,332
-4,069,019
-97% -$27.5M ﹤0.01% 1687
2019
Q3 		$31M Buy
4,199,351
+878,794
+26% +$8.67M 0.01% 852
2019
Q2 		$37.3M Buy
3,320,557
+22,782
+0.7% +$239K 0.01% 843
2019
Q1 		$35.5M Buy
3,297,775
+620,117
+23% +$9.17M 0.01% 854
2018
Q4 		$40.4M Buy
2,677,658
+2,150,556
+408% +$31.9M 0.01% 777
2018
Q3 		$9.75M Buy
527,102
+132,110
+33% +$3.01M ﹤0.01% 1287
2018
Q2 		$9.03M Sell
394,992
-24,360
-6% -$622K ﹤0.01% 1316
2018
Q1 		$11.9M Buy
419,352
+367,302
+706% +$10.5M ﹤0.01% 1229
2017
Q4 		$1.1M Buy
52,050
+5,674
+12% +$118K ﹤0.01% 1877
2017
Q3 		$842K Buy
46,376
+30,331
+189% +$473K ﹤0.01% 1931
2017
Q2 		$249K Buy
+16,045
New +$242K ﹤0.01% 2146
2016
Q2 		– Sell
-749,055
Closed -$9.66M – 2103
2016
Q1 		$9.66M Hold
749,055
– – ﹤0.01% 1152
2015
Q4 		$15.6M Buy
+749,055
New +$11.9M ﹤0.01% 1038

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Wellington Management Group's CTMX Position: Q2 2026 in Review

Wellington Management Group increased its CytomX Therapeutics (CTMX) stake by 44% in Q2 2026, buying an estimated $6.06M and bringing the position to 5,168,961 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1077.

Wellington Management Group first reported a position in CTMX in Q4 2015 and has held it in 15 quarters since. The position peaked at $40.4M in Q4 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Wellington Management Group held 5,168,961 shares of CytomX Therapeutics worth $19.4M as of Q2 2026.
  • Wellington Management Group bought 1,585,976 CytomX Therapeutics shares in Q2 2026, an estimated $6.06M.
  • CytomX Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1077 holding.
  • Wellington Management Group first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 15 quarters since.
  • Wellington Management Group's CytomX Therapeutics position peaked at $40.4M in Q4 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.